Paul Kelly Marcom, MD

Adjunct Professor in the Department of Medicine
Member of the Duke Cancer Institute
Campus mail 10 Bryan Searle Drive, Room 461 Seeley G. Mudd Building, Durham, NC 27710
Phone (919) 684-3877
Email address marco001@mc.duke.edu

Basic Science:
-Germline and somatic genetic changes in breast cancer.

Translational:
-Identification and management of individuals and families with hereditary cancer risk.
-Communication of cancer risk information to individuals and families.
-Breast cancer prevention.
-Optimizing management of early breast cancer.
-Treatment of metastatic breast cancer

Clinically, Dr. Marcom works as a medical oncologist in the multidisciplinary breast cancer clinic. He participates in clinical trials investigating new chemotherapeutic and biologic treatments. 

In Their Words

Education and Training

  • Fellow in Hematology-Oncology, Medicine, Duke University, 1992 - 1995
  • Medical Resident, Medicine, Duke University, 1989 - 1992
  • M.D., Baylor University, 1989

Publications

Ma, Cynthia X., Jingqin Luo, Rachel A. Freedman, Timothy J. Pluard, Julie R. Nangia, Janice Lu, Frances Valdez-Albini, et al. “The Phase II MutHER Study of Neratinib Alone and in Combination with Fulvestrant in HER2-Mutated, Non-amplified Metastatic Breast Cancer.” Clin Cancer Res 28, no. 7 (April 1, 2022): 1258–67. https://doi.org/10.1158/1078-0432.CCR-21-3418.

PMID
35046057
Full Text

Robinson, Timothy J., Lauren E. Wilson, P Kelly Marcom, Melissa Troester, Charles F. Lynch, Brenda Y. Hernandez, Edgardo Parrilla, Heather Ann Brauer, and Michaela A. Dinan. “Analysis of Sociodemographic, Clinical, and Genomic Factors Associated With Breast Cancer Mortality in the Linked Surveillance, Epidemiology, and End Results and Medicare Database.” Jama Netw Open 4, no. 10 (October 1, 2021): e2131020. https://doi.org/10.1001/jamanetworkopen.2021.31020.

PMID
34714340
Full Text

Paoletti, Costanza, Meredith M. Regan, Samuel M. Niman, Emily M. Dolce, Elizabeth P. Darga, Minetta C. Liu, P Kelly Marcom, et al. “Circulating tumor cell number and endocrine therapy index in ER positive metastatic breast cancer patients.” Npj Breast Cancer 7, no. 1 (June 11, 2021): 77. https://doi.org/10.1038/s41523-021-00281-1.

PMID
34117261
Full Text

Fayanju, Oluwadamilola M., Yi Ren, Ilona Stashko, Steve Power, Madeline J. Thornton, P Kelly Marcom, Terry Hyslop, and E Shelley Hwang. “Patient-reported causes of distress predict disparities in time to evaluation and time to treatment after breast cancer diagnosis.” Cancer 127, no. 5 (March 1, 2021): 757–68. https://doi.org/10.1002/cncr.33310.

PMID
33175437
Full Text

Tung, Nadine M., Mark E. Robson, Steffen Ventz, Cesar A. Santa-Maria, Rita Nanda, Paul K. Marcom, Payal D. Shah, et al. “TBCRC 048: Phase II Study of Olaparib for Metastatic Breast Cancer and Mutations in Homologous Recombination-Related Genes.” J Clin Oncol 38, no. 36 (December 20, 2020): 4274–82. https://doi.org/10.1200/JCO.20.02151.

PMID
33119476
Full Text

Mayer, E. L., V. Abramson, R. Jankowitz, C. Falkson, P. K. Marcom, T. Traina, L. Carey, et al. “TBCRC 030: a phase II study of preoperative cisplatin versus paclitaxel in triple-negative breast cancer: evaluating the homologous recombination deficiency (HRD) biomarker.” Ann Oncol 31, no. 11 (November 2020): 1518–25. https://doi.org/10.1016/j.annonc.2020.08.2064.

PMID
32798689
Full Text

Nichols, Brandon S., Erika Chelales, Roujia Wang, Amanda Schulman, Jennifer Gallagher, Rachel A. Greenup, Joseph Geradts, et al. “Quantitative assessment of distant recurrence risk in early stage breast cancer using a nonlinear combination of pathological, clinical and imaging variables.” J Biophotonics 13, no. 10 (October 2020): e201960235. https://doi.org/10.1002/jbio.201960235.

PMID
32573935
Full Text

Tung, Nadine, Banu Arun, Michele R. Hacker, Erin Hofstatter, Deborah L. Toppmeyer, Steven J. Isakoff, Virginia Borges, et al. “TBCRC 031: Randomized Phase II Study of Neoadjuvant Cisplatin Versus Doxorubicin-Cyclophosphamide in Germline BRCA Carriers With HER2-Negative Breast Cancer (the INFORM trial).” J Clin Oncol 38, no. 14 (May 10, 2020): 1539–48. https://doi.org/10.1200/JCO.19.03292.

PMID
32097092
Full Text

Gradishar, William J., Benjamin O. Anderson, Jame Abraham, Rebecca Aft, Doreen Agnese, Kimberly H. Allison, Sarah L. Blair, et al. “Breast Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology.” J Natl Compr Canc Netw 18, no. 4 (April 2020): 452–78. https://doi.org/10.6004/jnccn.2020.0016.

PMID
32259783
Full Text

Strickler, John H., Christel N. Rushing, Donna Niedzwiecki, Abigail McLeod, Ivy Altomare, Hope E. Uronis, S David Hsu, et al. “A phase Ib study of capecitabine and ziv-aflibercept followed by a phase II single-arm expansion cohort in chemotherapy refractory metastatic colorectal cancer.” Bmc Cancer 19, no. 1 (November 1, 2019): 1032. https://doi.org/10.1186/s12885-019-6234-8.

PMID
31675952
Full Text

Pages